• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

作为强效 HIV-1 NNRTIs 的 2,4,5-三取代嘧啶类化合物：合理设计、合成、活性评估及晶体结构研究。

2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies.

机构信息

Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, Jinan 250012, Shandong, PR China.

China-Belgium Collaborative Research Center for Innovative Antiviral Drugs of Shandong Province, 44 West Culture Road, Jinan 250012, Shandong, PR China.

出版信息

J Med Chem. 2021 Apr 8;64(7):4239-4256. doi: 10.1021/acs.jmedchem.1c00268. Epub 2021 Mar 18.

DOI:10.1021/acs.jmedchem.1c00268
PMID:33734714
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8594587/
Abstract

There is an urgent unmet medical need for novel human immunodeficiency virus type 1 (HIV-1) inhibitors that are effective against a variety of NNRTI-resistance mutations. We report our research efforts aimed at discovering a novel chemotype of anti-HIV-1 agents with improved potency against a variety of NNRTI-resistance mutations in this paper. Structural modifications of the lead led to the identification of a potent inhibitor . yielded highly potent anti-HIV-1 activities and improved resistance profiles compared with the approved drug etravirine. The co-crystal structure revealed the key role of the water networks surrounding the NNIBP for binding and for resilience against resistance mutations, while suggesting further extension of toward the NNRTI-adjacent site as a lead development strategy. Furthermore, demonstrated favorable pharmacokinetic and safety properties, suggesting the potential of as a promising anti-HIV-1 drug candidate.

摘要

目前，临床上急需能够有效应对多种 NNRTI 耐药突变的新型人类免疫缺陷病毒 1 型（HIV-1）抑制剂。本文报道了我们为发现具有新型结构的抗 HIV-1 药物而进行的研究工作，该药物对多种 NNRTI 耐药突变具有更好的抑制效果。通过对先导化合物进行结构修饰，我们发现了一种强效抑制剂 。该化合物对 HIV-1 具有很强的抑制活性，并改善了耐药谱，与已批准的药物依曲韦林相比具有更好的效果。共晶结构揭示了 NNIBP 周围的水分子网络在结合和抵御耐药突变方面的关键作用，同时也提示我们可以进一步将 向 NNRTI 相邻部位延伸，作为一种先导化合物开发策略。此外， 还表现出良好的药代动力学和安全性特征，这表明它有可能成为一种有前途的抗 HIV-1 药物候选物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b20/8594587/48aa0e174e6d/nihms-1750387-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b20/8594587/cc87799abafc/nihms-1750387-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b20/8594587/c919e673db10/nihms-1750387-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b20/8594587/4d28b2a1d70f/nihms-1750387-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b20/8594587/ffa35fe787c3/nihms-1750387-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b20/8594587/ddf4cf69e176/nihms-1750387-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b20/8594587/c193c3660019/nihms-1750387-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b20/8594587/48aa0e174e6d/nihms-1750387-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b20/8594587/cc87799abafc/nihms-1750387-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b20/8594587/c919e673db10/nihms-1750387-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b20/8594587/4d28b2a1d70f/nihms-1750387-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b20/8594587/ffa35fe787c3/nihms-1750387-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b20/8594587/ddf4cf69e176/nihms-1750387-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b20/8594587/c193c3660019/nihms-1750387-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b20/8594587/48aa0e174e6d/nihms-1750387-f0007.jpg

相似文献

1
2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies.作为强效 HIV-1 NNRTIs 的 2,4,5-三取代嘧啶类化合物：合理设计、合成、活性评估及晶体结构研究。
J Med Chem. 2021 Apr 8;64(7):4239-4256. doi: 10.1021/acs.jmedchem.1c00268. Epub 2021 Mar 18.
2
Development of Novel Dihydrofuro[3,4-]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C.开发新型二氢呋喃并[3,4-d]嘧啶衍生物作为 HIV-1 NNRTIs，以克服高度耐药突变株 F227L/V106A 和 K103N/Y181C。
J Med Chem. 2022 Feb 10;65(3):2458-2470. doi: 10.1021/acs.jmedchem.1c01885. Epub 2022 Jan 21.
3
Discovery of 2,4,6-trisubstituted pyrimidine derivatives as novel potent HIV-1 NNRTIs by exploiting the tolerant region II of the NNIBP.利用 NNIBP 的宽容区域 II 发现新型强效 HIV-1 NNRTIs 2,4,6-三取代嘧啶衍生物。
Eur J Med Chem. 2024 Nov 5;277:116708. doi: 10.1016/j.ejmech.2024.116708. Epub 2024 Jul 27.
4
Discovery of Novel Dihydrothiopyrano[4,3-]pyrimidine Derivatives as Potent HIV-1 NNRTIs with Significantly Reduced hERG Inhibitory Activity and Improved Resistance Profiles.发现新型二氢噻吩并[4,3-d]嘧啶衍生物作为强效 HIV-1 NNRTIs，具有显著降低 hERG 抑制活性和改善耐药性特征。
J Med Chem. 2021 Sep 23;64(18):13658-13675. doi: 10.1021/acs.jmedchem.1c01015. Epub 2021 Aug 25.
5
Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.发现并表征氟取代的二芳基嘧啶衍生物作为新型 HIV-1 NNRTIs，具有高度改善的耐药谱和对 hERG 离子通道的低活性。
J Med Chem. 2020 Feb 13;63(3):1298-1312. doi: 10.1021/acs.jmedchem.9b01769. Epub 2020 Jan 24.
6
Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties.基于结构的生物等排体方法产生了具有改善的耐药性特征和良好的药代动力学性质的 HIV-1 NNRTIs。
J Med Chem. 2020 May 14;63(9):4837-4848. doi: 10.1021/acs.jmedchem.0c00117. Epub 2020 Apr 22.
7
Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.BP-O-DAPY 和 O-DAPY 衍生物作为非核苷 HIV-1 逆转录酶抑制剂的分子设计、合成与生物评价。
Eur J Med Chem. 2013 Jul;65:134-43. doi: 10.1016/j.ejmech.2013.04.052. Epub 2013 May 3.
8
Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.基于生物等排体设计和对映体分析的手性羟基取代联苯二芳基嘧啶类非核苷 HIV-1 逆转录酶抑制剂。
Eur J Med Chem. 2020 Sep 15;202:112549. doi: 10.1016/j.ejmech.2020.112549. Epub 2020 Jul 2.
9
Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.鉴定二氢呋喃并[3,4-d]嘧啶衍生物为新型 HIV-1 非核苷类逆转录酶抑制剂，具有良好的抗病毒活性和理想的理化性质。
J Med Chem. 2019 Feb 14;62(3):1484-1501. doi: 10.1021/acs.jmedchem.8b01656. Epub 2019 Jan 18.
10
Structure-Based Optimization of 2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Exploiting the Tolerant Regions of the Non-Nucleoside Reverse Transcriptase Inhibitors' Binding Pocket.基于结构的 2,4,5-三取代嘧啶类化合物的优化作为有效的 HIV-1 非核苷逆转录酶抑制剂：利用非核苷逆转录酶抑制剂结合口袋的可容纳区域。
J Med Chem. 2023 Feb 9;66(3):2102-2115. doi: 10.1021/acs.jmedchem.2c01875. Epub 2023 Jan 26.

引用本文的文献

1
Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles.开发具有改善的耐药性和药代动力学特征的增强型HIV-1非核苷类逆转录酶抑制剂。
Sci Adv. 2025 May 30;11(22):eadt8916. doi: 10.1126/sciadv.adt8916.
2
Recent Advances in Pyrimidine-Based Drugs.基于嘧啶的药物的最新进展
Pharmaceuticals (Basel). 2024 Jan 11;17(1):104. doi: 10.3390/ph17010104.
3
Picomolar inhibitor of reverse transcriptase featuring significantly improved metabolic stability.逆转录酶的皮摩尔级抑制剂，具有显著提高的代谢稳定性。

本文引用的文献

1
Avoiding Drug Resistance in HIV Reverse Transcriptase.避免 HIV 逆转录酶的耐药性。
Chem Rev. 2021 Mar 24;121(6):3271-3296. doi: 10.1021/acs.chemrev.0c00967. Epub 2021 Jan 28.
2
Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years.非核苷类逆转录酶抑制剂（NNRTIs）的发展：我们的二十年历程。
Acta Pharm Sin B. 2020 Jun;10(6):961-978. doi: 10.1016/j.apsb.2019.11.010. Epub 2019 Nov 21.
3
Structure-Activity Relationship Exploration of NNIBP Tolerant Region I Leads to Potent HIV-1 NNRTIs.
Acta Pharm Sin B. 2023 Jul;13(7):3054-3066. doi: 10.1016/j.apsb.2023.03.022. Epub 2023 Mar 29.
4
Discovery of novel sulfonamide substituted indolylarylsulfones as potent HIV-1 inhibitors with better safety profiles.新型磺酰胺取代吲哚芳基砜作为具有更好安全性的强效HIV-1抑制剂的发现。
Acta Pharm Sin B. 2023 Jun;13(6):2747-2764. doi: 10.1016/j.apsb.2023.01.003. Epub 2023 Jan 11.
5
-Phenyl-1-(phenylsulfonyl)-1-1,2,4-triazol-3-amine as a New Class of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor.苯并[1,2,4]噻二唑-3-胺作为一种新型 HIV-1 非核苷类逆转录酶抑制剂。
J Med Chem. 2023 May 11;66(9):6193-6217. doi: 10.1021/acs.jmedchem.2c02055. Epub 2023 May 2.
6
Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.发现含哌嗪磺酰基的二芳基嘧啶衍生物作为有效的HIV-1非核苷类逆转录酶抑制剂。
Commun Chem. 2023 Apr 29;6(1):83. doi: 10.1038/s42004-023-00888-4.
7
Halo Library, a Tool for Rapid Identification of Ligand Binding Sites on Proteins Using Crystallographic Fragment Screening.Halo 文库：一种利用晶体筛选片段技术快速鉴定蛋白质配体结合位点的工具。
J Med Chem. 2023 May 11;66(9):6013-6024. doi: 10.1021/acs.jmedchem.2c01681. Epub 2023 Apr 28.
8
Targeting HIV-1 Reverse Transcriptase Using a Fragment-Based Approach.基于片段的方法靶向 HIV-1 逆转录酶。
Molecules. 2023 Mar 30;28(7):3103. doi: 10.3390/molecules28073103.
9
Identification of Boronate-Containing Diarylpyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.鉴定含硼酸酯的二芳基嘧啶衍生物作为新型 HIV-1 非核苷逆转录酶抑制剂。
Molecules. 2022 Nov 3;27(21):7538. doi: 10.3390/molecules27217538.
10
Newly Emerging Strategies in Antiviral Drug Discovery: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Anniversary.新兴抗病毒药物发现策略：谨以此文献给 Erik De Clercq 教授 80 周年华诞
Molecules. 2022 Jan 27;27(3):850. doi: 10.3390/molecules27030850.
结构-活性关系探索 NNIBP 耐受区域 I 导致有效的 HIV-1 NNRTIs。
ACS Infect Dis. 2020 Aug 14;6(8):2225-2234. doi: 10.1021/acsinfecdis.0c00327. Epub 2020 Jul 17.
4
Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-]pyrimidine derivatives as potent HIV-1 NNRTIs.探索NNIBP的疏水通道导致发现了新型哌啶取代的噻吩并[3,2 -]嘧啶衍生物，作为有效的HIV-1非核苷类逆转录酶抑制剂。
Acta Pharm Sin B. 2020 May;10(5):878-894. doi: 10.1016/j.apsb.2019.08.013. Epub 2019 Sep 14.
5
Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties.基于结构的生物等排体方法产生了具有改善的耐药性特征和良好的药代动力学性质的 HIV-1 NNRTIs。
J Med Chem. 2020 May 14;63(9):4837-4848. doi: 10.1021/acs.jmedchem.0c00117. Epub 2020 Apr 22.
6
Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.发现并表征氟取代的二芳基嘧啶衍生物作为新型 HIV-1 NNRTIs，具有高度改善的耐药谱和对 hERG 离子通道的低活性。
J Med Chem. 2020 Feb 13;63(3):1298-1312. doi: 10.1021/acs.jmedchem.9b01769. Epub 2020 Jan 24.
7
Water Networks Can Determine the Affinity of Ligand Binding to Proteins.水网络可以决定配体与蛋白质的结合亲和力。
J Am Chem Soc. 2019 Oct 9;141(40):15818-15826. doi: 10.1021/jacs.9b06275. Epub 2019 Sep 26.
8
Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.利用非核苷类逆转录酶抑制剂（NNRTI）结合口袋的耐受区域 I：发现对野生型和 E138K 突变病毒具有强大活性的二芳基嘧啶型 HIV-1 NNRTIs，同时显著提高了水溶性和有利的安全性特征。
J Med Chem. 2019 Feb 28;62(4):2083-2098. doi: 10.1021/acs.jmedchem.8b01729. Epub 2019 Feb 20.
9
Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.鉴定二氢呋喃并[3,4-d]嘧啶衍生物为新型 HIV-1 非核苷类逆转录酶抑制剂，具有良好的抗病毒活性和理想的理化性质。
J Med Chem. 2019 Feb 14;62(3):1484-1501. doi: 10.1021/acs.jmedchem.8b01656. Epub 2019 Jan 18.
10
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.HIV-1 非核苷类逆转录酶抑制剂（NNRTIs）从实验室到临床的历程。
J Med Chem. 2019 May 23;62(10):4851-4883. doi: 10.1021/acs.jmedchem.8b00843. Epub 2018 Dec 27.